HIV neutralization assay using polymerase chain reaction-derived molecular signals

Area of Science:

• Immunology
• Virology
• Molecular Biology

Background:

• Human polyclonal antibodies are critical for neutralizing human immunodeficiency virus (HIV).
• Assessing antibody neutralization capacity against diverse HIV isolates is vital for effective vaccine design.
• Existing methods may not fully capture the nuances of antibody-HIV interactions.

Purpose of the Study:

• To develop and validate a novel polymerase chain reaction (PCR)-based assay for quantifying HIV neutralization.
• To characterize the neutralization capacity of human polyclonal antibodies against both laboratory and patient-derived HIV isolates.
• To investigate isolate-dependent variations in HIV neutralization and their implications for vaccine development.

Main Methods:

• Development of a quantitative PCR-based assay to measure HIV proviral DNA formation as a marker of infection.
• Utilized laboratory strains (HIV-1-MN, HIV-IIIb) and primary wild-type patient isolates.
• Determined neutralization endpoints within 72 hours to minimize confounding factors.

Main Results:

• The assay reproducibly measured HIV neutralization by detecting the absence, diminution, or delayed kinetics of proviral DNA formation.
• Observed isolate-dependent variations in the relationship between p24 antigen production and proviral DNA formation.
• Identified disparities in antibody neutralization efficacy against prototype versus wild-type HIV isolates in peripheral blood mononuclear cells.

Conclusions:

• The developed PCR-based assay provides a sensitive and quantitative method to assess HIV neutralization.
• The findings highlight the importance of evaluating antibody responses against diverse and clinically relevant HIV isolates.
• This assay offers a valuable tool for understanding virus-antibody interactions and informing the development of broadly protective HIV vaccines.